Brokerage firm Jefferies Maintains its rating on TESARO Inc(NASDAQ:TSRO). In a research note issued to the investors, the brokerage major Raises the price-target to $80.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Aug 5, 2016.
In a different note, Baird said it Initiates Coverage on TESARO Inc, according to a research note issued on Jul 19, 2016. The shares have been rated ‘Outperform’ by the firm. On Jun 30, 2016, Jefferies said it Downgrades its rating on TESARO Inc. The shares have been rated ‘Hold’ by the firm. Credit Suisse said it Initiates Coverage on TESARO Inc, according to a research note issued on May 13, 2016. The shares have been rated ‘Outperform’ by the firm.
TESARO Inc (TSRO) made into the market gainers list on Wednesdays trading session with the shares advancing 0.36% or 0.34 points. Due to strong positive momentum, the stock ended at $94.99, which is also near the day’s high of $95.95. The stock began the session at $94.53 and the volume stood at 5,40,710 shares. The 52-week high of the shares is $97.9 and the 52 week low is $29.51. The company has a current market capitalization of $4,879 M and it has 5,13,65,707 shares in outstanding.
TESARO Inc(TSRO) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.56M. Analysts had an estimated revenue of $4.98M. Earnings per share were $-1.19. Analysts had estimated an EPS of $-1.71.
Several Insider Transactions has been reported to the SEC. On Jul 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 12,500 shares at $74.02 per share price.Also, On Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price.On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.